why choose us

First received: August 04, 2022

Clinical Trial: Add-on Reparixin in Adult Patients With ARDS

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Acute Respiratory Distress Syndrome, Adult

Study Type: INTERVENTIONAL


Official Title: Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO)

Brief Summary: Study objectivesTo characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ? 200).to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype.To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.

Read more